Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH
Status:
Completed
Trial end date:
2021-10-20
Target enrollment:
Participant gender:
Summary
This Study evaluates the pharmacokinetic (PK) profile of different zamicastat doses in
Pulmonary arterial hypertension (PAH) patients to find the most promising therapeutic dosage
range for the treatment of PAH disease